Yenfrino Gunadi - Pyridam Farma CFO Director
| PYFA Stock | IDR 260.00 4.00 1.52% |
Insider
Yenfrino Gunadi is CFO Director of Pyridam Farma Tbk
| Age | 37 |
| Phone | 62 21 5099 1067 |
| Web | https://www.pyfa.co.id |
Pyridam Farma Management Efficiency
The company has return on total asset (ROA) of (0.1653) % which means that it has lost $0.1653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.8717 %, meaning that it generated $0.8717 on every $100 dollars invested by stockholders. Pyridam Farma's management efficiency ratios could be used to measure how well Pyridam Farma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Fudoli Rustam | Indofarma Tbk | 53 | |
| Miranda Andamsari | Merck Tbk | N/A | |
| Kusuma Anjani | Mustika Ratu Tbk | 34 | |
| MM Apt | Kimia Farma Persero | 54 | |
| Perdana Octa | Mustika Ratu Tbk | 37 | |
| Rosrini | Kimia Farma Persero | 53 | |
| SE CA | Indofarma Tbk | 47 | |
| I Wijaya | Tempo Scan Pacific | 53 | |
| Kamelia Faisal | Indofarma Tbk | 54 | |
| Eva Fairus | Kimia Farma Persero | 56 | |
| Kartika Sutantio | Tempo Scan Pacific | N/A | |
| Pachita Ramadhani | Merck Tbk | 43 | |
| David Utama | Kimia Farma Persero | N/A | |
| D Virginia | Mustika Ratu Tbk | N/A | |
| Jejen Nugaha | Indofarma Tbk | 43 | |
| Rinita Daniati | Merck Tbk | N/A | |
| Aquira Moeladi | Merck Tbk | N/A | |
| MHum SS | Mustika Ratu Tbk | 90 | |
| Eduan Tjong | Merck Tbk | N/A | |
| Jasmine Karsono | Kimia Farma Persero | N/A | |
| Swasta Kusnadi | Tempo Scan Pacific | 62 | |
Management Performance
| Return On Equity | 0.87 | |||
| Return On Asset | -0.17 |
Pyridam Farma Tbk Leadership Team
Elected by the shareholders, the Pyridam Farma's board of directors comprises two types of representatives: Pyridam Farma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pyridam. The board's role is to monitor Pyridam Farma's management team and ensure that shareholders' interests are well served. Pyridam Farma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pyridam Farma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nadia Verdiana, Head Sec | ||
| Yoshiana, Head Unit | ||
| Joshua Sandjaja, HRD Mang | ||
| Andrey Septiana, Head OTC | ||
| Yenfrino Gunadi, CFO Director | ||
| Sinta Ningsih, Accounting, Fin | ||
| Yan Lee, Pres Director | ||
| Paulus Brotosaputro, Independent Director |
Pyridam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pyridam Farma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.87 | |||
| Return On Asset | -0.17 | |||
| Profit Margin | 0.36 % | |||
| Operating Margin | (0.37) % | |||
| Current Valuation | 1.29 T | |||
| Shares Outstanding | 535.08 M | |||
| Shares Owned By Insiders | 59.71 % | |||
| Shares Owned By Institutions | 7.48 % | |||
| Price To Book | 1.12 X | |||
| Price To Sales | 0.65 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Pyridam Stock
Pyridam Farma financial ratios help investors to determine whether Pyridam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pyridam with respect to the benefits of owning Pyridam Farma security.